SHERP

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation

Cited 0 time in webofscience Cited 215 time in scopus
Authors
Han, S. W.; Kim, T. Y.; Jeon, Y. K.; Hwang, P. G.; Im, S. A.; Lee, K. H.; Kim, J. H.; Kim, D. W.; Heo, D. S.; Kim, N. K.; Chung, D. H.; Bang, Y. J.
Issue Date
2006-04-15
Publisher
American Association for Cancer Research
Citation
Clin Cancer Res 2006;12:2538-44.
Keywords
AdultAgedAged, 80 and overAntineoplastic Agents/therapeutic useCarcinoma, Non-Small-Cell Lung/*drug therapy/genetics/metabolismDNA Mutational AnalysisFemaleGene DosageGenes, ras/*geneticsHumansIn Situ HybridizationLung Neoplasms/*drug therapy/genetics/metabolismMaleMiddle AgedMultivariate AnalysisMutation/geneticsPTEN Phosphohydrolase/metabolismPatient SelectionPhosphorylation/drug effectsProto-Oncogene Proteins c-akt/*metabolismQuinazolines/*therapeutic useReceptor, Epidermal Growth Factor/antagonists & inhibitors/*geneticsReceptor, erbB-2/geneticsSurvival Analysis
Abstract
PURPOSE: Mutations in epidermal growth factor receptor (EGFR) are strongly predictive of gefitinib efficacy in non-small-cell lung cancer. However, the presence of EGFR mutant nonresponses and nonmutant responses points out the need for more comprehensive analysis. Patients and Methods: For 69 non-small-cell lung cancer patients treated with gefitinib, we have extended our analysis to EGFR gene copy number by fluorescence in situ hybridization, mutations in K-ras, HER2, and exon 20 of EGFR by direct sequencing, and phosphatase and tensin homologue expression by immunohistochemistry, in addition to EGFR exons 18, 19, and 21, and phosphorylations of Akt and extracellular signal-regulated kinase reported previously. RESULTS: EGFR mutation and high gene copy number were associated with better objective response in univariate analysis. However, only gefitinib-sensitive EGFR mutation was independently predictive of both response (P = 0.011) and survival (P = 0.002) in multivariate analysis. No patients with K-ras mutation, including two EGFR mutants, showed response. In EGFR nonmutants, patients with either K-ras mutation or p-Akt overexpression exhibited poor response and time-to-progression whereas patients with high gene copy number tended to have better outcomes in univariate analysis. In multivariate analysis of time-to-progression in EGFR nonmutants, K-ras mutation or p-Akt overexpression was associated with shorter time-to-progression (P = 0.017). No patient with HER2 mutation showed response to gefitinib. Reduced phosphatase and tensin homologue expression was not associated with gefitinib sensitivity. CONCLUSION: Gefitinib-sensitive EGFR mutation is the single most important predictor of gefitinib sensitivity. In addition to EGFR mutation, K-ras mutation and Akt phosphorylation aid in better prediction of gefitinib responsiveness in non-small-cell lung cancer.
ISSN
1078-0432
Language
English
URI
http://hdl.handle.net/10371/10181
DOI
https://doi.org/10.1158/1078-0432.CCR-05-2845
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pathology (병리학전공)Journal Papers (저널논문_병리학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse